ALPS Medical Breakthroughs ETF (SBIO)
| Assets | $88.42M |
| Expense Ratio | 0.50% |
| PE Ratio | n/a |
| Shares Out | 2.40M |
| Dividend (ttm) | $1.17 |
| Dividend Yield | 3.07% |
| Ex-Dividend Date | Dec 19, 2024 |
| Payout Ratio | n/a |
| 1-Year Return | +2.86% |
| Volume | 44,730 |
| Open | 37.04 |
| Previous Close | 36.84 |
| Day's Range | 37.04 - 38.17 |
| 52-Week Low | 22.33 |
| 52-Week High | 42.73 |
| Beta | 0.77 |
| Holdings | 108 |
| Inception Date | Dec 31, 2014 |
About SBIO
Fund Home PageThe ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is issued by SS&C.
Top 10 Holdings
28.84% of assets| Name | Symbol | Weight |
|---|---|---|
| Rhythm Pharmaceuticals, Inc. | RYTM | 3.61% |
| Avidity Biosciences, Inc. | RNA | 3.34% |
| Cytokinetics, Incorporated | CYTK | 3.15% |
| Axsome Therapeutics, Inc. | AXSM | 3.15% |
| Metsera, Inc. | MTSR | 2.88% |
| Nuvalent, Inc. | NUVL | 2.77% |
| Merus N.V. | MRUS | 2.68% |
| Krystal Biotech, Inc. | KRYS | 2.47% |
| Crinetics Pharmaceuticals, Inc. | CRNX | 2.40% |
| PTC Therapeutics, Inc. | PTCT | 2.40% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 19, 2024 | $1.17346 | Dec 26, 2024 |
| Dec 21, 2023 | $0.07106 | Dec 27, 2023 |
| Dec 19, 2019 | $0.01585 | Dec 27, 2019 |
| Dec 20, 2018 | $0.7841 | Dec 27, 2018 |
| Dec 21, 2017 | $0.57949 | Dec 28, 2017 |
News
3 Stocks Driving Biotech ETF SBIO's Appeal
In the shifting landscape of ETFs, many funds claim to offer exposure to innovation. Technology plays a key role as a growth industry and a driver for performance across the economy overall, as well.
This Underrated Tech ETF Is Spiking Amid Rate Cut Hype
Looking to add some diversification and upside to your equities allocation? While the broader tech space has largely relied on just a handful of names, smaller subcategories in innovative tech also ha...
Is Biotech the Right Tech ETF Move Right Now? SBIO Argues Yes
The tech ETF space offers plenty of important questions for investors.
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...
SBIO ETF: Betting On Medical Breakthroughs
ALPS Medical Breakthroughs ETF is rated Hold due to high fees, low yield, and mixed performance compared to other healthcare ETFs. The SBIO ETF focuses on small and mid-cap biotech companies with drug...
Advacam & Vector Space Biosciences sign Letter of Intent (LOI) to Develop AI Models & CubeSat Payloads for the Space Industry
LA JOLLA, Calif.--(BUSINESS WIRE)---- $SBIO #Advacam--Advacam, provider of radiation detectors that map radiation aboard the International Space Station (ISS) and Vector Space Biosciences (crypto symb...
Vector Space Biosciences (SBIO) Is Now Available for Trading on LBank Exchange
Road Town, Virgin Islands--(Newsfile Corp. - September 24, 2023) - LBank Exchange, a global digital asset trading platform, listed Vector Space Biosciences (SBIO) on September 15, 2023. For all users ...
